MoonLake Immunotherapeutics (MLTX) director granted options on 22,195 shares

Rhea-AI Filing Summary

MoonLake Immunotherapeutics director Loy Spike received a compensation-related stock option grant. The award covers 22,195 options to buy Class A ordinary shares at an exercise price of $19.19 per share, with no cash paid for the grant itself.

The option vests in full on the earlier of June 17, 2027 or the company’s next annual general meeting of shareholders, as long as Spike continues to serve the company. The option expires on June 17, 2036 if not exercised.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Loy Spike

Role null

Type	Security	Shares	Price	Value
Grant/Award	Option to Buy	22,195	$0.00	--

Holdings After Transaction: Option to Buy — 22,195 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Options granted: 22,195 options Exercise price: $19.19 per share Expiration date: June 17, 2036 +3 more

6 metrics

Options granted 22,195 options Grant covering Class A ordinary shares

Exercise price $19.19 per share Stock option strike price

Expiration date June 17, 2036 Option term end date

Shares underlying options 22,195 shares Class A ordinary shares subject to option

Shares following transaction 22,195 derivative shares Total optioned shares held after grant

Vesting date trigger Earlier of June 17, 2027 or next AGM Full vesting condition with continued service

Key Terms

Option to Buy, Class A ordinary shares, exercise price, vest in full, +1 more

5 terms

Option to Buy financial

"security_title: "Option to Buy""

Class A ordinary shares financial

"underlying_security_title: "Class A ordinary shares, par value $0.0001 per share""

Class A ordinary shares are a type of ownership stake in a company that typically grants voting rights to shareholders, allowing them to have a say in important company decisions. They often come with priority in receiving dividends or profits, making them attractive to investors seeking influence and potential income. These shares help distinguish different levels of ownership and rights within a company's stock structure.

exercise price financial

"conversion_or_exercise_price: "19.1900""

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vest in full financial

"which will vest in full the earlier of (i) June 17, 2027"

annual general meeting of shareholders financial

"the date of the Issuer's next annual general meeting of shareholders"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Loy Spike

(Last) (First) (Middle)

C/O MOONLAKE IMMUNOTHERAPEUTICS

DORFSTRASSE 29

(Street)

ZUG 6300

(City) (State) (Zip)

SWITZERLAND

(Country)

2. Issuer Name and Ticker or Trading Symbol
MoonLake Immunotherapeutics [ MLTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/17/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Option to Buy	$19.19	06/17/2026		A		22,195		(1)	06/17/2036	Class A ordinary shares, par value $0.0001 per share	22,195	$0.00	22,195	D

Explanation of Responses:

1. This option represents a right to purchase a total of 22,195 Class A Ordinary Shares of the Issuer, which will vest in full the earlier of (i) June 17, 2027 and (ii) the date of the Issuer's next annual general meeting of shareholders, subject to the Reporting Person's continued service to the Issuer.

	/s/ Matthias Bodenstedt, Attorney-in-fact for Spike Loy	06/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did MoonLake Immunotherapeutics (MLTX) director Loy Spike report on this Form 4?

Loy Spike reported receiving a stock option grant covering 22,195 Class A ordinary shares of MoonLake Immunotherapeutics. The options were granted as compensation and give the right to buy shares at a fixed $19.19 exercise price before the 2036 expiration date.

How many MoonLake Immunotherapeutics (MLTX) shares are covered by Loy Spike’s new options?

The option grant covers 22,195 underlying Class A ordinary shares of MoonLake Immunotherapeutics. These shares can be purchased by exercising the options at the specified $19.19 exercise price once the options have vested according to the stated vesting schedule.

What is the exercise price and expiration date of Loy Spike’s MoonLake (MLTX) options?

The options have an exercise price of $19.19 per share and expire on June 17, 2036. This means Spike can choose to buy the underlying shares at $19.19 any time after vesting and before the June 17, 2036 expiration, subject to plan terms.

When do Loy Spike’s MoonLake Immunotherapeutics (MLTX) options vest?

The options vest in full on the earlier of June 17, 2027 or the date of MoonLake Immunotherapeutics’ next annual general meeting of shareholders. Vesting is conditioned on Loy Spike’s continued service to the company through that vesting date as disclosed.

Does this MoonLake Immunotherapeutics (MLTX) Form 4 show an open-market stock purchase or sale?

The Form 4 does not show any open-market purchase or sale. It reports a compensation-related grant of stock options with transaction code “A,” which represents a grant or award acquisition rather than a market trade in existing MoonLake Immunotherapeutics shares.